ProShare Advisors LLC decreased its position in Omeros Corporation (NASDAQ:OMER) by 20.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,563 shares of the biopharmaceutical company’s stock after selling 7,286 shares during the period. ProShare Advisors LLC owned approximately 0.06% of Omeros Corporation worth $417,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Allied Advisory Services Inc. acquired a new position in Omeros Corporation during the fourth quarter valued at about $108,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Omeros Corporation during the fourth quarter valued at $263,000. Raymond James Financial Services Advisors Inc. boosted its position in shares of Omeros Corporation by 52.1% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 34,258 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 11,734 shares in the last quarter. Rubric Capital Management LP purchased a new position in shares of Omeros Corporation during the fourth quarter valued at $496,000. Finally, Teachers Advisors LLC boosted its position in shares of Omeros Corporation by 9.2% in the fourth quarter. Teachers Advisors LLC now owns 63,334 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 5,347 shares in the last quarter. 45.44% of the stock is owned by institutional investors.
Omeros Corporation (NASDAQ OMER) traded up 3.20% during midday trading on Monday, hitting $24.51. The stock had a trading volume of 1,744,973 shares. Omeros Corporation has a 1-year low of $7.20 and a 1-year high of $25.10. The stock’s market cap is $1.08 billion. The company has a 50-day moving average of $16.37 and a 200-day moving average of $12.93.
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The company had revenue of $12.26 million for the quarter, compared to analysts’ expectations of $13.32 million. During the same quarter in the prior year, the firm earned ($0.54) EPS. Omeros Corporation’s quarterly revenue was up 65.2% compared to the same quarter last year. Equities research analysts forecast that Omeros Corporation will post ($1.32) EPS for the current year.
Several brokerages have recently commented on OMER. FBR & Co reaffirmed a “buy” rating on shares of Omeros Corporation in a report on Saturday, April 1st. Maxim Group set a $19.00 price objective on Omeros Corporation and gave the stock a “buy” rating in a research note on Saturday, March 11th. Cantor Fitzgerald lowered Omeros Corporation from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $21.00 to $15.00 in a research report on Thursday, May 11th. Wedbush reissued an “outperform” rating and set a $47.00 price objective on shares of Omeros Corporation in a report on Wednesday, May 10th. Finally, ValuEngine raised Omeros Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $32.66.
In other news, Director Thomas J. Cable sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $16.49, for a total transaction of $49,470.00. Following the sale, the director now owns 40,067 shares in the company, valued at $660,704.83. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Michael A. Jacobsen sold 12,000 shares of the stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $24.95, for a total transaction of $299,400.00. Following the sale, the vice president now owns 19,500 shares in the company, valued at approximately $486,525. The disclosure for this sale can be found here. Insiders have sold 39,000 shares of company stock worth $857,670 in the last quarter. 13.60% of the stock is owned by corporate insiders.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with our FREE daily email newsletter.